Welcome to our dedicated page for Immunovia Ab news (Ticker: IMMVF), a resource for investors and traders seeking the latest updates and insights on Immunovia Ab stock.
Immunovia AB (IMMVF) generates news primarily around its efforts to develop and commercialize blood-based tests for early detection of pancreatic cancer. Company updates often highlight progress in clinical studies, performance data for its tests, and steps toward commercialization in key markets such as the United States. Because Immunovia focuses on high-risk individuals and early-stage disease, its announcements frequently center on how its tests perform in specialized clinical cohorts.
News releases commonly cover results from major studies, including CLARITI and VERIFI for the company’s next-generation pancreatic cancer test and PanFAM-1 for familial and hereditary high-risk populations. These updates provide details on sensitivity, specificity and comparisons with existing biomarkers such as CA19-9, as well as the role of Immunovia’s tests alongside imaging-based surveillance.
Investors and healthcare observers can also expect news on Immunovia’s commercialization plans, including targeted launches of its next-generation test, engagement with high-risk surveillance centers, and initiatives aimed at reimbursement and regulatory pathways. The company has reported on rights issues and warrant programs that fund clinical and commercial activities, and on organizational developments intended to support its focus on the U.S. diagnostics market.
This news feed aggregates press releases and market communications related to Immunovia’s diagnostic tests, clinical collaborations, financing activities and strategic priorities. Users interested in the evolution of blood-based pancreatic cancer diagnostics, high-risk surveillance programs and the company’s progress toward broader market adoption can follow this page for ongoing updates.
Immunovia AB announces the resignation of Chief Technology Officer, Dr. Peter Schultz-Knappe, effective August 31, 2020. Hans Christian Pedersen, previously Vice-President of Business Development, will take on expanded responsibilities as Vice President of Strategy and Business Development. This transition aims to support the upcoming Q4 2020 launch of the IMMray™ PanCan-d test, which is designed for early pancreatic cancer detection. The company is prepared to enhance its commercialization efforts as it approaches this significant milestone.
Immunovia AB will host its second webinar on the IMMray™ PanCan-d on September 2, 2020, at 16:00 CET. The webinar will discuss the results from the Commercial Test Model Study and provide updates on the launch activities of the IMMray™ PanCan-d test, designed for early pancreatic cancer detection. Presenters include experts Linda Mellby, Thomas King, and Laura Chirica. The IMMray™ PanCan-d is in its final validation phase and aims for market launch in Q4 2020, potentially becoming the first blood-based pancreatic cancer diagnostic tool.
Immunovia reported its second quarter results for January to June 2020, emphasizing resilience amid COVID-19 challenges. The company plans to launch the IMMray™ PanCan-d test for early pancreatic cancer detection by Q4 2020. A significant capital raise of approximately SEK 400 million was completed, aiding commercialization efforts. The quarter saw the reopening of the Marlborough laboratory, which had faced operational delays due to the pandemic. Immunovia remains committed to its mission, recently engaging stakeholders through a virtual investment day.
Immunovia AB announced a second webinar about its IMMray™ PanCan-d product, scheduled for September 2, 2020, at 16:00 CET. This session will discuss results from the Commercial Test Model Study and provide updates on launch activities. Presenters include Linda Mellby (PhD), Thomas King (MD, PhD), and Laura Chirica (PhD). A live Q&A will follow the webinar. Access details will be shared on August 27, 2020. IMMray™ PanCan-d aims to be the first blood test for early pancreatic cancer detection, enhancing patient outcomes.